4DMedical Signs Distribution Agreement with Blackford

26 February 2024 

Highlights 

• 4DMedical partners with Blackford to distribute its Imbio medical imaging AI solutions 

• The Blackford Platform™ is a leading medical imaging AI marketplace that has a broad portfolio of third party clinical applications available to its customers 

• The Blackford Platform™ is also the leading white-label platform that underlies other major radiology companies’ AI offerings, including Philips Healthcare, Bayer Radiology, and Intelerad Medical Systems, all of whom can now be resellers of Imbio AI solutions 

• Combined with Imbio’s existing distribution agreements with Nuance and Aidoc, the Blackford agreement means 4DMedical now has partnerships with the three leading medical imaging AI marketplaces for Imbio AI solutions 

Melbourne, Australia, 26 February 2024: Respiratory imaging technology company 4DMedical Limited (ASX:4DX, “4DMedical”, or the “Company”) today announces the signing of an agreement with Blackford Analysis Inc (“Blackford” or “the Blackford Platform™”) to distribute Imbio’s medical imaging AI solutions. 

Medical imaging AI marketplaces like the Blackford Platform™ are an important part of the medical AI ecosystem, as many hospital radiology departments prefer to purchase a wide array of AI solutions through a one-stop-shop rather than dealing with the commercial, legal and technical complexity of multiple individual providers. 

The Blackford Platform™ is a medical imaging AI marketplace that is recognised as a global industry leader in consolidating disparate AI clinical applications. The platform provides access to AI technologies through integration, workflow, orchestration, and reporting, and will now host the Imbio product portfolio. 

Expanded AI marketplace agreement with Blackford 

Established in 2010, Blackford is one of the world’s leading radiology AI marketplaces, with a broad portfolio of third-party applications covering many clinical indications. 

Blackford has differentiated itself from other providers by successfully positioning itself as the leading white-label platform that supports other major radiology companies' AI offerings. The Blackford white labelled AI platform services major radiology companies today including Bayer Radiology, Intelerad Medical Systems and Merative (formerly IBM Watson Health), with more strategic partnerships under development. Notably, Blackford also provides the white-labelled AI platform for Philips Healthcare. 

Combined with Imbio’s existing distribution agreements with Nuance (Microsoft) and Aidoc, the Blackford agreement means 4DMedical now has partnerships with the three leading medical imaging AI marketplaces for Imbio AI solutions.

4DMedical MD/CEO and Founder Andreas Fouras said: 

We are incredibly excited to be partnering with Blackford as a distributor of Imbio’s AI solutions. This deal positions our Imbio products with a comprehensive distribution network across the three leading platforms connecting AI providers with hospitals, doctors and their patients. With established contracts and recurring revenue, five new technologies in clinical use, and a very strong product pipeline, Imbio has incredible operational momentum in its own right. We are particularly excited by the opportunities for Imbio technology to provide solutions for the VA, and look forward to sharing further progress over the coming weeks and months. 

–ENDS– 

Authorised by the 4DMedical Board of Directors.

Contacts

Corporate Chief Financial Officer Simon Glover sglover@4dmedical.com 

Administration Company Secretary Naomi Lawrie companysecretary@4dmedical.com 

Media Enquiries The Capital Network (TCN) Julia Maguire julia@thecapitalnetwork.com.au

About 4DMedical 

4DMedical Limited (ASX:4DX) is a global medical technology company that has created a step change in the capacity to accurately and quickly understand the lung function of patients with respiratory diseases. Through its flagship patented XV Technology®, 4DMedical enables physicians to understand regional airflow in the lungs and identify respiratory deficiencies earlier and with greater sensitivity as they breathe. This technology powers 4DMedical's FDA-cleared XV Lung Ventilation Analysis Software (XV LVAS®) ̶ the first modality to dynamically quantify ventilation throughout the lungs, and its Computed Tomography enabled counterpart software, CT LVAS™. XV LVAS® and CT LVAS™ reports are prepared using 4DMedical's Software as a Service delivery model using existing hospital imaging equipment or the Company's revolutionary XV Scanner. In December 2023, 4DMedical acquired Imbio, a leader in artificial intelligence medical imaging solutions for chronic lung and cardiothoracic diseases. Imbio’s regulatory-cleared solutions transform the way patients are discovered, diagnosed, and treated, enabling physician productivity and more personalised care for patients. To learn more, please visit www.4dmedical.com and www.imbio.com.